We’ve recently updated our valuation analysis.

Insulet Valuation

Is PODD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PODD?

Other financial metrics that can be useful for relative valuation.

PODD key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue16.9x
Enterprise Value/EBITDA166.9x
PEG Ratio23.8x

Price to Sales Ratio vs Peers

How does PODD's PS Ratio compare to its peers?

The above table shows the PS ratio for PODD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average4.8x
STE STERIS
4.5x6.5%US$21.4b
HOLX Hologic
4.7x5.3%US$20.8b
BAX Baxter International
1.5x3.8%US$22.8b
RMD ResMed
8.6x7.7%US$32.5b
PODD Insulet
16.3x15.3%US$20.3b


Price to Earnings Ratio vs Industry

How does PODD's PE Ratio compare vs other companies in the US Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.5%
n/an/an/a


Price to Sales Ratio vs Fair Ratio

What is PODD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PODD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio16.3x
Fair PS Ratio6.7x

Price-To-Sales vs Fair Ratio: PODD is expensive based on its Price-To-Sales Ratio (16.3x) compared to the estimated Fair Price-To-Sales Ratio (6.7x).


Share Price vs Fair Value

What is the Fair Price of PODD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PODD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$292.17
US$311.63
+6.7%
11.7%US$350.00US$216.00n/a16
Jan ’24US$294.39
US$309.94
+5.3%
12.0%US$350.00US$216.00n/a16
Dec ’23US$308.00
US$302.13
-1.9%
12.0%US$350.00US$216.00n/a16
Nov ’23US$266.07
US$276.63
+4.0%
12.5%US$345.00US$190.00n/a16
Oct ’23US$229.40
US$278.79
+21.5%
12.4%US$345.00US$190.00n/a14
Sep ’23US$259.53
US$276.40
+6.5%
12.5%US$345.00US$190.00n/a15
Aug ’23US$245.68
US$260.13
+5.9%
13.5%US$345.00US$190.00n/a15
Jul ’23US$226.46
US$264.13
+16.6%
14.1%US$345.00US$190.00n/a15
Jun ’23US$207.38
US$272.25
+31.3%
13.3%US$345.00US$190.00n/a16
May ’23US$238.99
US$285.76
+19.6%
14.9%US$357.00US$190.00n/a17
Apr ’23US$279.02
US$286.56
+2.7%
14.8%US$357.00US$190.00n/a18
Mar ’23US$260.84
US$286.56
+9.9%
14.8%US$357.00US$190.00n/a18
Feb ’23US$248.08
US$300.56
+21.2%
13.8%US$357.00US$190.00US$290.5316
Jan ’23US$266.07
US$310.56
+16.7%
13.2%US$357.00US$190.00US$294.3916
Dec ’22US$283.46
US$309.65
+9.2%
12.9%US$357.00US$190.00US$308.0017
Nov ’22US$308.70
US$286.68
-7.1%
11.1%US$340.00US$190.00US$266.0719
Oct ’22US$285.33
US$285.37
+0.01%
10.5%US$325.00US$190.00US$229.4019
Sep ’22US$299.99
US$285.37
-4.9%
10.5%US$325.00US$190.00US$259.5319
Aug ’22US$279.69
US$282.79
+1.1%
10.6%US$325.00US$190.00US$245.6819
Jul ’22US$278.59
US$280.16
+0.6%
9.9%US$323.00US$190.00US$226.4619
Jun ’22US$264.47
US$278.84
+5.4%
10.3%US$323.00US$190.00US$207.3819
May ’22US$295.22
US$282.22
-4.4%
10.5%US$323.00US$190.00US$238.9918
Apr ’22US$264.82
US$279.39
+5.5%
11.3%US$323.00US$174.00US$279.0218
Mar ’22US$270.26
US$275.22
+1.8%
10.7%US$323.00US$174.00US$260.8418
Feb ’22US$263.75
US$260.33
-1.3%
12.1%US$323.00US$174.00US$248.0818


Discover undervalued companies